JPS5665828A - Antitumor agent - Google Patents
Antitumor agentInfo
- Publication number
- JPS5665828A JPS5665828A JP14215279A JP14215279A JPS5665828A JP S5665828 A JPS5665828 A JP S5665828A JP 14215279 A JP14215279 A JP 14215279A JP 14215279 A JP14215279 A JP 14215279A JP S5665828 A JPS5665828 A JP S5665828A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- antibody
- purity
- tumor
- antitumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 229940100198 alkylating agent Drugs 0.000 abstract 3
- 239000002168 alkylating agent Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 208000007093 Leukemia L1210 Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- SGDBTWWWUNNDEQ-UHFFFAOYSA-N Merphalan Chemical compound OC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000006268 Sarcoma 180 Diseases 0.000 abstract 1
- 238000001042 affinity chromatography Methods 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229960004630 chlorambucil Drugs 0.000 abstract 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 229960001055 uracil mustard Drugs 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
NEW MATERIAL:A substance obtained by subjecting a high-purity antibody to tumor antigen, prepared by purification through affinity chromatography, and an antitumor alkylating agent having at least one amino group or carboxyl group to amide bond.
EXAMPLE: An amide bond substance of a high-purity immunoglobulin induced from an antigen of human cancer, e.g., sarcoma 180, Sato's lung cancer, leukemia L-1210, Ehrlich cancer, etc. and an alkylating agent, e.g., chlorambucil, merphalan, uramustine, etc.
USE: An antitumor agent. Since the agent is bonded to a high-purity antibody to a tumor antigen, it can be transferred efficiently to tumor parts of the body, and it can exhibit antitumor effect. Normal cell, therefore, are damaged slightly and the agent has small side effects.
PROCESS: A tumor cell is injected hypodermically to an animal, which is immunized to give an antibody which is purified. The high-purity antibody and an alkylating agent are subject to amido bond.
COPYRIGHT: (C)1981,JPO&Japio
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14215279A JPS5665828A (en) | 1979-11-02 | 1979-11-02 | Antitumor agent |
US06/103,474 US4315851A (en) | 1978-12-29 | 1979-12-14 | Pharmaceutical composition having antitumor activity |
SE7910483A SE7910483L (en) | 1978-12-29 | 1979-12-19 | PHARMACEUTICAL COMPOSITION WITH TUMOR INHIBITION EFFECT |
PH23447A PH16902A (en) | 1978-12-29 | 1979-12-20 | Pharmaceutical composition having anti-tumor activity |
GB7944494A GB2038836B (en) | 1978-12-29 | 1979-12-28 | Antitumour substance |
CH11501/79A CH655010A5 (en) | 1978-12-29 | 1979-12-28 | PHARMACEUTICAL ACTIVE SUBSTANCE WITH ANTITUM ORACTIVITY. |
FR797932054A FR2445149B1 (en) | 1978-12-29 | 1979-12-28 | PHARMACEUTICAL COMPOSITION HAVING ANTI-TUMOR ACTIVITY |
DE2952690A DE2952690C2 (en) | 1978-12-29 | 1979-12-29 | Antitumor substance, process for their preparation and pharmaceutical agent containing them |
IT28464/79A IT1127324B (en) | 1978-12-29 | 1979-12-31 | Antitumour compsn. contg. high purity antibody |
US06/321,486 US4401592A (en) | 1978-12-29 | 1981-11-16 | Pharmaceutical composition having antitumor activity |
SE8406510A SE8406510L (en) | 1978-12-29 | 1984-12-20 | PHARMACEUTICAL COMPOSITION WITH TUMOR INHIBITION EFFECT |
SE8406511A SE8406511D0 (en) | 1978-12-29 | 1984-12-20 | PHARMACEUTICAL COMPOSITION WITH TUMOR INHIBITION EFFECT |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14215279A JPS5665828A (en) | 1979-11-02 | 1979-11-02 | Antitumor agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5665828A true JPS5665828A (en) | 1981-06-03 |
JPS6256136B2 JPS6256136B2 (en) | 1987-11-24 |
Family
ID=15308563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14215279A Granted JPS5665828A (en) | 1978-12-29 | 1979-11-02 | Antitumor agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5665828A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58118520A (en) * | 1982-01-09 | 1983-07-14 | Hidematsu Hirai | Antitumor proteinic complex and preparation thereof |
JPS62142123A (en) * | 1983-04-08 | 1987-06-25 | Kureha Chem Ind Co Ltd | Antitumor agent bonded with human immunoglobulin |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0470125U (en) * | 1990-10-25 | 1992-06-22 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4962194A (en) * | 1972-05-10 | 1974-06-17 | ||
JPS5161640A (en) * | 1974-09-20 | 1976-05-28 | Searle & Co | Koshuyozaino seizoho |
JPS51144723A (en) * | 1975-05-27 | 1976-12-13 | Yeda Res & Dev | Antiitumor agent |
JPS5592325A (en) * | 1978-12-29 | 1980-07-12 | Kureha Chem Ind Co Ltd | Antitumor agent and its preparation |
-
1979
- 1979-11-02 JP JP14215279A patent/JPS5665828A/en active Granted
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4962194A (en) * | 1972-05-10 | 1974-06-17 | ||
JPS5161640A (en) * | 1974-09-20 | 1976-05-28 | Searle & Co | Koshuyozaino seizoho |
JPS51144723A (en) * | 1975-05-27 | 1976-12-13 | Yeda Res & Dev | Antiitumor agent |
JPS5592325A (en) * | 1978-12-29 | 1980-07-12 | Kureha Chem Ind Co Ltd | Antitumor agent and its preparation |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58118520A (en) * | 1982-01-09 | 1983-07-14 | Hidematsu Hirai | Antitumor proteinic complex and preparation thereof |
JPS62142123A (en) * | 1983-04-08 | 1987-06-25 | Kureha Chem Ind Co Ltd | Antitumor agent bonded with human immunoglobulin |
Also Published As
Publication number | Publication date |
---|---|
JPS6256136B2 (en) | 1987-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IT8223795A0 (en) | GAMMA), ITS VEHICLES OF POLYPEPTIDES CONTAINING THE EXPRESSION SEQUENCE, THEIR PROCEDURE OF INTERFERON AMINO ACIDS PREPARATION, HUMAN IMMUNE COMPOSITIONS (HUMAN INTERFERON PHARMACEUTICALS CONTAINING SUCH POLYPEPTIDES. | |
GB2102810B (en) | Human interferon-related peptides antigens antibodies and process for preparing the same | |
DK0458878T3 (en) | New monoclonal antibody to a new antigen associated with human tumors | |
ES521741A0 (en) | PROCEDURE FOR THE PREPARATION OF NEW BICYCLE AMINO ACIDS. | |
EP0536275A4 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof | |
ZA872166B (en) | Synthetic htlv-iii peptides,compositions and uses thereof | |
EP0643559A4 (en) | RECIPTOR-BINDING REGION OF THE DIPHTHERIETOXIUS. | |
MX6452A (en) | BICYCLE AMINO ACIDS AND PROCEDURE FOR THEIR PREPARATION. | |
NZ213535A (en) | Purified polyclonal antibody that binds selectively to the marker epitope encompassing amino acid position 12 of an activated form of oncogenic p21 protein | |
IL68201A0 (en) | Peptides with the specificity of foot and mouth disease viral antigens and compositions and methods for treating animals using the same | |
ES2071628T3 (en) | PROTEIN SEPARATION A FROM ANTIBODY PREPARATIONS. | |
NL191583C (en) | Pre-products for essential and semi-essential amino acids in the body and method for the preparation of these pre-products. | |
EP0674661A4 (en) | Assay and treatment for demyelinating diseases such as multiple sclerosis. | |
IT8319160A0 (en) | PROCESS FOR THE SYNTHESIS OF PEPTIDES AND AMINO ACIDS BLOCKING AGENTS. | |
DE69126577D1 (en) | Antigenic peptide for the detection of anti-hepatitis C virus antibodies and its use | |
AR227021A1 (en) | PROCEDURE FOR THE PREPARATION OF HIGHLY PURIFIED PROTEIN COMPLEX CONCENTRATES | |
GR852541B (en) | ||
JPS5665828A (en) | Antitumor agent | |
ZA833483B (en) | In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins | |
JPS5665829A (en) | Antitumor agent | |
EP0412970A4 (en) | Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein | |
FR2315916A2 (en) | THERAPEUTIC MIXTURES INCLUDING ANALOGUES ALPHA HYDROXY ACIDS OF ESSENTIAL AMINO ACIDS AND THEIR ADMINISTRATION TO HUMANS FOR THE IMPROVEMENT OF PROTEIN SYNTHESIS AND THE SUPPRESSION OF UREA FORMATION | |
JPS5592325A (en) | Antitumor agent and its preparation | |
FR2555755B1 (en) | METHOD FOR DETERMINING HUMAN IMMUNOGLOBULINS WHICH ARE SPECIFIC TO HUMAN CANCER ANTIGENS AND APPLICATION OF THIS METHOD IN THE SERODIAGNOSIS OF PRIMITIVE TUMOR DISEASES | |
FI92716C (en) | New monoclonal antibodies to IFN-Omega, their methods of preparation and their use for the purification and detection of IFN-Omega |